SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences reports marginal rise in Q4 consolidated net profit

09 May 2018 Evaluate

Jubilant Life Sciences has reported results for fourth quarter and year ended March 31, 2018.   

The company has reported over three-fold jump in its net profit at Rs 86.39 crore for the quarter ended March 31, 2018 as compared to Rs 25.83 crore for the same quarter in the previous year. Total income of the company increased by 26.28% to Rs 972.32 crore for quarter under review as compared to Rs 770.00 crore for the quarter ended March 31, 2017. 

On consolidated basis, the company has reported marginal rise of 3.16% in its net profit at Rs 154.87 crore for the quarter ended March 31, 2018 as compared to Rs 150.13 crore for the corresponding quarter in the FY17. Total consolidated income of the company increased by 37.71% at Rs 2,274.87 crore for quarter under review as compared to Rs 1,651.95 crore for the same quarter ended previous year.  

For the year ended March 31, 2018, the company has posted over three-fold jump in its net profit at Rs 263.44 crore as compared to Rs 79.19 crore for the same period in the previous year. Total income of company increased by 26.71% to Rs 3,389.22 crore for year under review as compared to Rs 2,674.88 crore for the period ended March 31, 2017.  

For the year ended March 31, 2018, on the consolidated basis, the company has posted rise of 11.67% in its net profit at Rs 642.81 crore as compared to Rs 575.65 crore for the same period in the previous year. Total consolidated income of company increased by 25.98% to Rs 7,597.84 crore for year under review as compared to Rs 6,031.18 crore for the period ended March 31, 2017.

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×